Physician profile
Victor Fernandez
NPI 1255645255
$3,436.15
in general payments reported to CMS, 2019-2025
23 companies · $803 in 2025
The $803 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $59.33 · 2020: $95.91 · 2021: $667 · 2022: $556 · 2023: $501 · 2024: $754 · 2025: $803.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,058.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,058.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $810.50 | 2021-2025 | Parsabiv, Tavneos, Aranesp |
| Horizon Therapeutics Plc | $545.35 | 2021-2023 | Krystexxa |
| Bayer Healthcare Pharmaceuticals INC. | $467.13 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $269.54 | 2021-2025 | Farxiga |
| Otsuka America Pharmaceutical, INC. | $218.88 | 2021-2025 | Jynarque |
| Ani Pharmaceuticals, INC. | $202.69 | 2025 | Purified Cortrophin Gel |
| Calliditas Therapeutics US INC. | $194.17 | 2022-2025 | Tarpeyo |
| Glaxosmithkline, LLC. | $141.21 | 2021-2025 | Benlysta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $114.32 | 2024-2025 | Jardiance |
| Akebia Therapeutics INC | $63.98 | 2020 | |
| Fresenius USA Marketing, INC. | $62.41 | 2021-2025 | Velphoro, Velphoro |
| Mallinckrodt Enterprises LLC | $59.33 | 2019 | |
| Novo Nordisk INC | $51.29 | 2025 | Ozempic |
| Vifor Pharma, INC. | $47.26 | 2022-2023 | Korsuva, Veltassa |
| Daiichi Sankyo INC. | $34.29 | 2021-2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $31.93 | 2020 | |
| Opko Pharmaceuticals, LLC | $28.40 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $23.80 | 2021 | |
| Aurinia Pharma U.S., INC. | $22.20 | 2023 | Lupkynis |
| Invivyd INC | $17.64 | 2025 | Pemgarda |
| Novartis Pharmaceuticals Corporation | $16.77 | 2024 | |
| Alexion Pharmaceuticals, INC. | $13.06 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Victor Fernandez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.